IMMIX BIOPHARMA, INC. Income Taxes Paid
IMMIX BIOPHARMA, INC. (IMMX) reported Income Taxes Paid of $14.32 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:IncomeTaxesPaidNet · last filed 2026-08-07
- IMMIX BIOPHARMA, INC. income taxes paid, net for the quarter ending 2025-09-30 was $7.72K, a 30.71% decline year-over-year.
- IMMIX BIOPHARMA, INC. income taxes paid, net for the quarter ending 2025-06-30 was $8.91K, a 13.20% decline year-over-year.
- IMMIX BIOPHARMA, INC. income taxes paid, net for the quarter ending 2025-03-31 was $9.82K, a 11.12% increase year-over-year.
- IMMIX BIOPHARMA, INC. income taxes paid, net for the quarter ending 2024-09-30 was $11.14K, a 63.71% increase year-over-year.
- IMMIX BIOPHARMA, INC. income taxes paid, net for fiscal 2020 was $17.55K.
| Period end | Income Taxes Paid, Net 3 month | Income Taxes Paid, Net 6 month | Income Taxes Paid, Net 9 month | Income Taxes Paid, Net 12 month |
|---|---|---|---|---|
| 2026-06-30 | $14.32K 10-Q · filed 2026-08-07 | |||
| 2025-09-30 | $7.72K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $16.64K derived: sum of 2 quarters · filed 2026-08-07 | $26.46K 10-Q · filed 2025-11-07 | |
| 2025-06-30 | $8.91K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $18.74K 10-Q · filed 2026-08-07 | ||
| 2025-03-31 | $9.82K 10-Q · filed 2026-05-07 | |||
| 2024-09-30 | $11.14K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $21.41K derived: sum of 2 quarters · filed 2025-11-07 | $30.25K 10-Q · filed 2025-11-07 | |
| 2024-06-30 | $10.27K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $19.11K 10-Q · filed 2025-08-08 | ||
| 2024-03-31 | $8.84K 10-Q · filed 2025-05-08 | |||
| 2023-09-30 | $6.81K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $13.16K derived: sum of 2 quarters · filed 2024-11-12 | $18.33K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $6.35K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $11.52K 10-Q · filed 2024-08-12 | ||
| 2023-03-31 | $5.17K 10-Q · filed 2024-05-09 | |||
| 2022-03-31 | $1.62K 10-Q · filed 2023-05-12 | |||
| 2020-12-31 | $17.55K 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |